Cromwell Holdings LLC Purchases Shares of 1,178 Moderna, Inc. $MRNA

Cromwell Holdings LLC purchased a new stake in shares of Moderna, Inc. (NASDAQ:MRNA) in the second quarter, according to the company in its most recent filing with the SEC. The firm purchased 1,178 shares of the company’s stock, valued at approximately $33,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Bank of New York Mellon Corp lifted its position in Moderna by 1.8% during the first quarter. Bank of New York Mellon Corp now owns 1,918,248 shares of the company’s stock valued at $54,382,000 after purchasing an additional 34,034 shares during the last quarter. Wealthfront Advisers LLC raised its position in shares of Moderna by 143.3% during the 1st quarter. Wealthfront Advisers LLC now owns 31,018 shares of the company’s stock valued at $879,000 after buying an additional 18,268 shares in the last quarter. FORA Capital LLC lifted its holdings in shares of Moderna by 31.7% during the 1st quarter. FORA Capital LLC now owns 97,072 shares of the company’s stock worth $2,752,000 after acquiring an additional 23,344 shares during the last quarter. Jump Financial LLC grew its position in Moderna by 5,590.0% in the first quarter. Jump Financial LLC now owns 902,427 shares of the company’s stock worth $25,584,000 after acquiring an additional 886,567 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in Moderna by 12.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 2,629,865 shares of the company’s stock worth $74,557,000 after acquiring an additional 285,662 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Stock Performance

NASDAQ:MRNA opened at $28.49 on Friday. The firm has a market cap of $11.08 billion, a PE ratio of -3.78 and a beta of 2.01. Moderna, Inc. has a fifty-two week low of $23.15 and a fifty-two week high of $62.11. The business has a 50 day moving average price of $26.30 and a 200-day moving average price of $27.41.

Moderna (NASDAQ:MRNA) last issued its earnings results on Friday, August 1st. The company reported ($2.13) EPS for the quarter, topping the consensus estimate of ($2.99) by $0.86. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The company had revenue of $142.00 million for the quarter, compared to the consensus estimate of $116.26 million. During the same period in the previous year, the firm earned ($3.33) earnings per share. The firm’s revenue for the quarter was down 41.1% on a year-over-year basis. Moderna has set its FY 2025 guidance at EPS. Research analysts predict that Moderna, Inc. will post -9.61 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Leerink Partners lowered their price target on Moderna from $18.00 to $15.00 and set an “underperform” rating on the stock in a research report on Friday, August 22nd. Wells Fargo & Company reissued an “equal weight” rating on shares of Moderna in a report on Sunday, July 13th. Cowen started coverage on Moderna in a research note on Sunday, July 13th. They issued a “hold” rating for the company. Evercore ISI set a $32.00 price target on shares of Moderna in a research report on Friday, August 1st. Finally, Citigroup initiated coverage on shares of Moderna in a report on Friday, August 1st. They issued a “neutral” rating and a $40.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, fourteen have issued a Hold rating and five have given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $41.81.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.